Intellia Therapeutics (NASDAQ:NTLA) Announces Quarterly Earnings Results, Beats Estimates By $0.16 EPS

Intellia Therapeutics (NASDAQ:NTLA) posted its quarterly earnings results on Thursday. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.16, Briefing.com reports. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The firm had revenue of $23.02 million during the quarter, compared to the consensus estimate of $12.17 million. During the same period last year, the company earned ($1.27) earnings per share. The business’s revenue was up 78.4% compared to the same quarter last year.

Here are the key takeaways from Intellia Therapeutics’ conference call:

• The company expects a pivotal readout for lonvo-z by mid‑year with a planned BLA submission in the second half of the year, positioning it as potentially the world’s first pivotal in vivo CRISPR gene‑editing readout.
• Commercial preparations for lonvo-z are underway—field medical hires, payer engagement, validated CMC/commercial manufacturing, and market research showing very high patient and HCP interest—which the company says could enable a launch and meaningful revenue that materially reduces future capital needs.
• The nex‑z ATTR program remains disrupted by a clinical hold on the MAGNITUDE cardiomyopathy trial following liver enzyme elevations and a patient death; MAGNITUDE‑2 (polyneuropathy) was reopened with added liver monitoring, steroid‑trigger guidance, and tighter screening, while MAGNITUDE is still under active FDA discussion.
• Financials show cash, cash equivalents, and marketable securities of $605.1 million at year‑end (down from $861.7M), which management says should fund operations into H2 2027 and support key milestones despite a Q4 net loss of $95.8M.

Intellia Therapeutics Stock Performance

NTLA traded down $0.46 on Friday, reaching $13.83. The company had a trading volume of 2,036,448 shares, compared to its average volume of 5,135,204. The stock has a market cap of $1.60 billion, a P/E ratio of -3.23 and a beta of 2.10. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.25. The company’s fifty day moving average is $11.80 and its 200 day moving average is $13.00.

Insiders Place Their Bets

In other news, CEO John M. Leonard sold 34,146 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the sale, the chief executive officer owned 1,013,339 shares in the company, valued at $9,332,852.19. The trade was a 3.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the completion of the transaction, the executive vice president directly owned 98,533 shares in the company, valued at $907,488.93. The trade was a 7.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 53,051 shares of company stock worth $488,600 over the last three months. Insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in shares of Intellia Therapeutics in the fourth quarter valued at about $245,000. Invesco Ltd. raised its stake in Intellia Therapeutics by 5.8% in the 4th quarter. Invesco Ltd. now owns 433,290 shares of the company’s stock worth $3,895,000 after purchasing an additional 23,870 shares in the last quarter. Axxcess Wealth Management LLC boosted its holdings in Intellia Therapeutics by 20.1% in the 4th quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company’s stock valued at $192,000 after purchasing an additional 3,583 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth approximately $90,000. Finally, XTX Topco Ltd acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth approximately $402,000. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics News Roundup

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Q4 results beat consensus — Intellia reported EPS of ($0.83) vs. ($0.99) expected and revenue of $23.0M (well above estimates), showing 78% YoY revenue growth; the beat supports near‑term credibility on commercial-readiness messaging. Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
• Positive Sentiment: Pipeline and commercial timeline clarity — management outlined HAELO Phase 3 timing for lonvo‑z (topline mid‑2026), a planned BLA submission in H2‑2026 and potential U.S. launch in 1H‑2027, which frames a clear path to first commercial revenue. Intellia Announces Q4 & Business Updates
• Positive Sentiment: FDA lifts clinical hold on MAGNITUDE‑2 — the hold on the MAGNITUDE‑2 trial of nex‑z was lifted, removing a specific regulatory overhang for that study and reducing execution risk for the ATTRv‑PN program. FDA lifts clinical hold on MAGNITUDE-2
• Positive Sentiment: Analyst support — Chardan Capital reaffirmed a Buy and set a $26 price target, signaling bullish conviction from at least one boutique research shop and giving investors a sizable upside reference. Benzinga
• Neutral Sentiment: Long‑term analyst upgrades vs. near‑term losses — Brookline Capital revised up FY2028/2029 EPS forecasts substantially (FY2029 to $46.29), implying strong long‑term expectations, but these are years out and do not alter near‑term cash‑burn dynamics.
• Neutral Sentiment: Earnings call and transcripts available — management emphasized strategic progress on lonvo‑z and nex‑z and commercial readiness, but the materials also highlighted the cash runway and execution plans rather than immediate profitability. Earnings Call Transcript
• Negative Sentiment: Regulatory uncertainty remains for MAGNITUDE (ATTR‑CM) — while MAGNITUDE‑2 was cleared, Intellia continues engagement with the FDA to resolve a clinical hold on the MAGNITUDE Phase 3 ATTR‑CM trial, leaving program risk and timing uncertainty. Company Press Release
• Negative Sentiment: Still unprofitable and volatile — Intellia reported a large negative net margin and consensus still forecasts negative EPS for the current fiscal year; that keeps the stock sensitive to execution and trial updates, which can drive sharp swings.

Wall Street Analyst Weigh In

NTLA has been the topic of a number of recent analyst reports. Oppenheimer set a $27.00 target price on shares of Intellia Therapeutics in a report on Friday, November 7th. Wells Fargo & Company decreased their price objective on shares of Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating for the company in a research report on Friday, November 7th. Barclays dropped their target price on shares of Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating on the stock in a report on Friday, November 7th. Citizens Jmp cut their target price on shares of Intellia Therapeutics from $29.00 to $21.00 and set a “market outperform” rating for the company in a research note on Friday, November 7th. Finally, Wedbush lowered their price target on Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Intellia Therapeutics has an average rating of “Hold” and a consensus price target of $17.48.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.